Sage Journals: Discover world-class research

Abstract

Goal

The goal of this program is to inform the participant of practical ways to prevent, identify, and manage the extravasation of anti-neoplastic agents.

Objectives

At the completion of this program the participant will be able to:

List antineoplastic agents known to be vesicants or irritants.

Identify the signs and symptoms of extravasation injury.

Recommend a procedure for the safe administration of vesicant medications.

Describe the appropriate management of antineoplastic-induced extravasation injury.

Keywords

adverse reaction antineoplastic agents chemotherapy extravasation intravenous administration vesicant

Get full access to this article

View all access options for this article.

References

Black

Vein extravasation: A severe complication of I.V. therapy. Parenterals. 1988; 2: 5–7.

Mateu

, Alzamora

, Fanco

Needlestick injuries and hazardous drugs. Am J Health Syst Pharm. 1996; 53: 1068, 1071.

Larson

D.L.

Treatment of tissue extravasation by antitumor agents. Cancer. 1982; 49: 1796–99.

Cox

, Stuart-Harris

, Abdini

The management of cytotoxic-drug extravasation: Guide-lines drawn up by a working party for the Clinical Oncological Society of Australia. Med J Aust. 1988; 148: 185–89.

Dorr

R.T.

Antidotes to vesicant chemotherapy extravasations. Blood Rev. 1990; 4: 41–60.

Terry

, Baranowski

, Lonsway

R.A.

. eds. Intravenous Therapy: Clinical Principles and Practice. Philadelphia, PA: W.B. Saunders; 1995: 260–2, 422–3.

Boyle

D.M.

, Engelking

Vesicant extravasation: Myths and realities. Oncol Nurs Forum. 1995; 22: 57–67.

Fish

L.S.

The prevention and extravasation of antineoplastic agents. Hospital Pharmacy Hotline. 1990; 3: 1–3.

Parashos

P.J.

A rational approach for the management of tissue extravasation due to antineoplastic drugs. MicroLink Update. April 1986; 2: 13–5.

10.

Oncology Nursing Society Clinical Practice Committee. Cancer Chemotherapy Guidelines: Recommendations for the Management of Vesicant Extravasation, Hypersensitivity, and Anaphylaxis. Philadelphia, PA: Oncology Nursing Press; 1992.

11.

Rudolph

Larson DL. Etiology and treatment of chemotherapeutic agent extravasation injuries: A review. J Clin Oncol. 1987; 5: 1116–26.

12.

Ignoffo

R.J.

, Friedman

M.A.

Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev. 1980; 7: 17–27.

13.

Dorr

R.T.

Pharmacologic management of vesicant chemotherapy extravasation. In: Dorr

R.T.

, Von Hoff

D.D.

, eds. Cancer Chemotherapy Handbook. 2nd ed. Norwalk, CT: Appleton & Lange; 1994, 109–18.

14.

Wood

L.S.

, Gullo

S.M.

IV vesicants: How to avoid extravasation. Am J Nurs. 1993; 93: 42–6.

15.

Zenk

K.E.

Management of intravenous extravasations. Infusion. 1981; 5: 77–9.

16.

Lokich

J.J.

, Moore

Drug extravasation in cancer chemotherapy [letter]. Ann Intern Med. 1986; 104: 124.

17.

Moore

, Strong

, Childress

Surveillance of the patient receiving infusional cancer chemotherapy: Nursing role in recognition and management of catheter-related complications. J Infus Chemother. 1996; 6: 171–80.

18.

Banerjee

, Brotherston

T.M.

, Lamberty

B.G.H.

Cancer chemotherapy agent-induced perivenous extravasation injuries. Postgrad Med J. 1987; 63: 5–9.

19.

Lauvin

, Miglianico

, Hellegouarc

H.R.

Skin cancer occurring 10 years after the extravasation of doxorubicin. N Engl J Med. 1995; 332: 754.

20.

Bertelli

Prevention and management of extravasation of cytotoxic drugs. Drug Safety. 1995; 12: 245–55.

21.

Shenaq

S.M.

, Abbase

E.A.

, Friedman

J.D.

Soft-tissue reconstruction following extravasation of chemotherapeutic agents. Surg Oncol Clin N Am. 1996; 5: 825–45.

22.

Birdsall

, Naliboff

A.R.

How do you manage chemotherapy extravasation?

Am J Nurs. 1988; 88: 228–30.

23.

Smith

Prevention and treatment of extravasation. Br J Paren Ther. 1985; 6: 114–20.

24.

Holmes

B.C.

Administration of cancer chemotherapy agents. In: Dorr

R.T.

, Von Hoff

D.D.

, eds. Cancer Chemotherapy Handbook. 2nd ed. Norwalk, CT: Appleton & Lange; 1994, 57–94.

25.

Jameson

, O'Donnell

Guidelines for extravasation of intravenous drugs. Infusion. 1983; 7: 157–61, 165.

26.

Hirsh

J.D.

, Conlon

P.F.

Implementing guidelines for managing extravasation of antineoplastics. Am J Hosp Pharm. 1983; 40: 1516–19.

27.

Flemmer

, Chan

J.S.L.

A pediatric protocol for management of extravasation injuries. Pediatr Nurs. 1993; 19: 355–58, 424.

28.

Wolfe

C.A.

, Linkewich

J.A.

Preparation of guidelines for the avoidance and treatment of extravasation due to anti-neoplastic drugs. Hosp Pharm. 1987; 22: 125–31.

29.

Hankin

F.M.

, Louis

D.S.

Extravasation of chemotherapeutic agents. Am Fam Physician. 1985; 31: 147–50.

30.

Hessen

J.A.

Protocol for treatment of vesicant antineoplastic extravasation. Hosp Pharm. 1989; 24: 705–9.

31.

Dini

, Forno

, Gozza

Combined management in the treatment of epidoxorubicin extravasation. Support Care Cancer. 1995; 3: 150–2.

32.

Dorr

, Soble

M.J.

, Liddil

J.D.

Mitomycin-C skin toxicity studies in mice: Reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. J Clin Oncol. 1986; 4: 1399–1404.

33.

Bertelli

, Gozza

, Forno

G.B.

Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: A prospective clinical study. J Clin Oncol. 1995; 13: 2851–55.

34.

Olver

I.N.

, Aisner

, Hament

A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation. J Clin Oncol. 1988; 6: 1732–5.

35.

Ludwig

C.U.

, Stoll

, Obrist

Prevention of cytotoxic drug induced skin ulcers with dimethyl sulfoxide (DMSO) and a-tocopherole. Eur J Cancer Clin Oncol. 1987; 23: 327–329.

36.

Lawrence

H.J.

, Goodnight

S.H.

Dimethyl sulfoxide and extravasation of anthracycline agents. Ann Intern Med. 1983; 98: 1025.

37.

Alberts

D.S.

, Dorr

R.T.

Case report: Topical DMSO for mitomycin-C induced skin ulceration. Oncol Nurs Forum. 1991; 18: 693–5.

38.

Lawrence

H.J.

, Walsh

, Zapotowski

K.A.

Topical dimethylsulfoxide may prevent tissue damage from anthracycline extravasation. Cancer Chemother Pharmacol. 1989; 23: 316–8.

39.

Larson

D.L.

What is the appropriate management of tissue extravasation by antitumor agents?

Plast Reconstr Surg. 1985; 75: 397–402.

40.

Olver

I.N.

, Schwarz

M.A.

Use of dimethyl sulfoxide in limiting tissue damage caused by extravasation of doxorubicin. Cancer Treat Rep. 1983; 67: 407–8.

41.

McEvoy

G.K.

, Litvak

, Welsh

O.H.

., eds. AHFS 99 Drug Information. Bethesda, MD: American Society of Health-System Pharmacists; 1999.

42.

Mosby's GenRx: The Complete Reference for Generic and Brand Drugs. St. Louis, MO: Mosby Inc.; 1999.

43.

DepoCyt (cytarabine liposome injection) package insert. San Diego, CA/Emeryville, CA: DepoTech Corporation/Chiron Therapeutics; April 1999.

44.

Dezube

B.J.

Safety assessment: Doxil (doxorubicin HCl liposome injection) in refractory AIDS-related Kaposi's sarcoma. Doxil Clinical Series. Menlo Park, CA: Sequus Pharmaceuticals; 1997, 1–7.

45.

Gabizon

A.A.

Liposomal anthracyclines. Hematol Oncol Clin North Am. 1994; 8: 431–50.

46.

Davis

M.E.

, DeSantis

, Klemm

A flow sheet for follow-up after chemotherapy extravasation. Oncol Nurs Forum. 1995; 22: 979–83.

47.

Amonafide. In: Dorr

, Von Hoff

eds. Cancer Chemotherapy Handbook. 2nd ed. Norwalk, CT: Appleton & Lange; 1994, 175–82.

48.

Echinomycin. In: Dorr

, Von Hoff

eds. Cancer Chemotherapy Handbook. 2nd ed. Norwalk, CT: Appleton & Lange; 1994, 416–9.

49.

Esorubicin. In: Dorr

, Von Hoff

eds. Cancer Chemotherapy Handbook. 2nd ed. Norwalk, CT: Appleton & Lange; 1994, 439–43.

50.

Piroxantrone. In: Dorr

, Von Hoff

eds. Cancer Chemotherapy Handbook. 2nd ed. Norwalk, CT: Appleton & Lange; 1994, 791–4.

51.

Kara

, Ross

Severe soft tissue necrosis after extravasation of mitox-antrone: Case report. Can J Plast Surg. 1998; 6: 204–6.

52.

Bailey

W.L.

, Crump

R.M.

Taxol extravasation: A case report. Can Oncol Nurs J. 1997; 7: 96–9.

53.

Bicher

, Levenback

, Burke

T.W.

Infusion site soft-tissue injury after paclitaxel administration. Cancer. 1995; 76: 116–20.

54.

Finley

R.S.

Administration of cancer chemotherapy. In: Finlay

R.S.

, Balmer

, eds. Concepts in Oncology Therapeutics. 2nd edition. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 1998, 173–95.

55.

Busulfex (busulfan) injection package insert. Minnetonka, MN: Orphan Medical; February 1999.

56.

Berg

Irinotecan hydrochloride: Drug profile and nursing implications of a topoisomerase I inhibitor in patients with advanced colorectal cancer. Oncol Nurs Forum. 1998; 25: 535–43.

57.

Valstar (valrubicin) sterile solution for intravesical instillation package insert. Bedford, OH/Rochester, NY: Ben Venue Laboratories/Medeva Pharmaceuticals, Inc.; June 1998.

Prevention and Management of Antineoplastic Extravasation Injury

Abstract

Goal

Objectives

Keywords

Get full access to this article

References